The latest price target for Kazia Therapeutics (NASDAQ:KZIA) was reported by HC Wainwright & Co. on July 12, 2024. The analyst firm set a price target for $2.00 expecting KZIA to fall to within 12 months (a possible -62.89% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Kazia Therapeutics (NASDAQ:KZIA) was provided by HC Wainwright & Co., and Kazia Therapeutics reiterated their buy rating.

The last upgrade for Kazia Therapeutics Ltd happened on April 11, 2023 when HC Wainwright & Co. raised their price target to $2. HC Wainwright & Co. previously had a neutral for Kazia Therapeutics Ltd.

The last downgrade for Kazia Therapeutics Ltd happened on August 2, 2022 when Maxim Group changed their price target from N/A to N/A for Kazia Therapeutics Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kazia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kazia Therapeutics was filed on July 12, 2024 so you should expect the next rating to be made available sometime around July 12, 2025.

While ratings are subjective and will change, the latest Kazia Therapeutics (KZIA) rating was a reiterated with a price target of $2.00 to $2.00. The current price Kazia Therapeutics (KZIA) is trading at is $5.39, which is out of the analyst’s predicted range.